Supportive treatments

Comparison of the CELLEX™ and UVAR-XTS™ closed-system extracorporeal photopheresis devices in the treatment of chronic graft-versus-host disease. Whittle RM et al. J Clin Apher. 2017 Jun 13. doi: 10.1002/jca.21541. [Epub ahead of print]. Comparison of Operative Time with Conventional Fluoroscopy versus Spinal Neuronavigation in Instrumented Spinal Tumor Surgery. Miller JA et al. World Neurosurg. 2017 Jun 9. pii: S1878-8750(17)30908-7. doi: 10.1016/j.wneu.2017.06.016.…

Details
Journal, Library, Myeloma Prognosis & Outcomes

Complications of myeloma and its treatments

Molecular mechanisms, current management and next generation therapy in myeloma bone disease. Heusschen R et al. Leuk Lymphoma. 2017 Jun 2:1-15. doi: 10.1080/10428194.2017.1323272. [Epub ahead of print]. An unusual presentation of multiple myeloma with unilateral sudden vision loss: A case report. Wu PW et al. Medicine (Baltimore). 2017 Jun;96(25):e7277. doi: 10.1097/MD.0000000000007277. Metabolic Syndrome in Long-Term Survivors of Hematopoietic Stem-Cell Transplantation. Ragbourne SC et al. Clin Lymphoma Myeloma Leuk. 2017 Jun;17(6):340-346.…

Details
Journal, Library, Management of complications & side effects

Current treatments

Comparison of cyclophosphamide-thalidomide-dexamethasone to bortezomib-cyclophosphamide-dexamethasone as induction therapy for multiple myeloma patients in Brazil. Vigolo S et al. Hematol Oncol Stem Cell Ther. 2017 Jun 15. pii: S1658-3876(17)30082-1. doi: 10.1016/j.hemonc.2017.05.027. [Epub ahead of print]. Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone. Vogl DT et al. Leuk Lymphoma. 2017 Jun 22:1-8. doi: 10.1080/10428194.2017.1334125. [Epub ahead of…

Details
Journal, Library

Publication of consensus statement on the use of plerixafor in myeloma or lymphoma patients

A consensus statement identifying the best use of plerixafor to facilitate autologous peripheral stem cell collection to support high-dose therapy and stem cell transplantation in myeloma or lymphoma patients has been published recently in the Journal of Clinical Apheresis. Written by the Plerixafor Usage Working Party Group involving representative clinicians from the UK and Republic…

Details
News

NICE recommends carfilzomib for restricted use in England and Wales

The National Institute for Health and Care Excellence (NICE) has published a final appraisal determination (FAD) recommending the use of carfilzomib (Kyprolis®) in combination with dexamethasone for myeloma patients at first relapse who have not previously received bortezomib (Velcade®). Carfilzomib will immediately be available to eligible patients in England via interim funding arrangements through the…

Details
News

IMWG publishes consensus on second primary malignancies in myeloma

The International Myeloma Working Group (IMWG) has published a consensus statement providing practical recommendations for managing myeloma patients who develop second primary malignanices (SPMs). Published in the Annals of Oncology, the group reviewed the latest evidence of possible host-, disease- and treatment-related risk factors for the development of SPMs in myeloma patients. They recommend that…

Details
News

Diagnostic techniques and prognostic indicators

Identification of pathway-based prognostic gene signatures in patients with multiple myeloma. Zamani-Ahmadmahmudi M et al. Transl Res. 2017 May 9. pii: S1931-5244(17)30041-5. doi: 10.1016/j.trsl.2017.05.001. [Epub ahead of print]. Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy. Łuczak M, Kubicki T et al. Pol Arch Intern Med. 2017 May 25. doi: 10.20452/pamw.4032. [Epub ahead of…

Details
Diagnosing and Monitoring Myeloma, Journal, Library

Related conditions

Incidence, characteristics and outcome of solitary plasmacytoma and plasma cell leukemia. Population based data from the Swedish Myeloma Register. Nahi H et al. Eur J Haematol. 2017 May 22. doi: 10.1111/ejh.12907. [Epub ahead of print]. Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma. Salem DA et al. Leuk Lymphoma. 2017…

Details
Journal, Library

Emerging treatments

Haematological cancer: Pembrolizumab is effective in multiple myeloma. Sidaway P. Nat Rev Clin Oncol. 2017 May 23. doi: 10.1038/nrclinonc.2017.76. [Epub ahead of print]. A Phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractorymultiple myeloma. Martin T et al. Blood. 2017 May 8. pii: blood-2016-09-740787. doi: 10.1182/blood-2016-09-740787. [Epub ahead of print]. Pembrolizumab, pomalidomide and low dose dexamethasone for relapsed/refractory multiple myeloma.…

Details
Journal, Library